Read More 1 minute read Analyst Ratings News Price Target Citigroup Maintains Buy on Luminar Technologies, Lowers Price Target to $19 By Benzinga Newsdesk Today, 4:40 AM Citigroup analyst Itay Michaeli maintains Luminar Technologies (NASDAQ:LAZR) with a Buy and lowers the price target from $20 to $19. LAZR
Read More 1 minute read Analyst Ratings News Price Target Citigroup Maintains Buy on Kinetik Holdings, Lowers Price Target to $34 By Benzinga Newsdesk Today, 4:40 AM Citigroup analyst Spiro Dounis maintains Kinetik Holdings (NYSE:KNTK) with a Buy and lowers the price target from $35 to $34. KNTK
Read More 1 minute read Analyst Ratings News Price Target HSBC Maintains Buy on Lufax Holding, Lowers Price Target to $3 By Benzinga Newsdesk Today, 4:40 AM HSBC analyst Carson Lo maintains Lufax Holding (NYSE:LU) with a Buy and lowers the price target from $4 to $3. LU
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $7 Price Target By Benzinga Newsdesk Today, 4:40 AM HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $7 price target. ONCT
Read More 1 minute read Analyst Ratings News Price Target HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Lowers Price Target to $26 By Benzinga Newsdesk Today, 4:40 AM HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $27 to $26. CRBU
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $15 Price Target By Benzinga Newsdesk Today, 4:40 AM HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $15 price target. ONCY
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $50 Price Target By Benzinga Newsdesk Today, 4:40 AM HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $50 price target. AMLX
Read More 1 minute read Analyst Ratings News Price Target Upgrades B of A Securities Upgrades Portland Gen Electric to Buy, Announces $52 Price Target By Benzinga Newsdesk Today, 4:40 AM B of A Securities analyst Julien Dumoulin-Smith upgrades Portland Gen Electric (NYSE:POR) from Neutral to Buy and announces $52 price target. POR
Read More 1 minute read Analyst Ratings Initiation News Price Target Jefferies Initiates Coverage On Academy Sports with Buy Rating, Announces Price Target of $73 By Benzinga Newsdesk Today, 4:40 AM Jefferies analyst Anna Glaessgen initiates coverage on Academy Sports (NASDAQ:ASO) with a Buy rating and announces Price Target of $73. ASO
Read More 1 minute read Analyst Ratings Downgrades News Price Target JP Morgan Downgrades Ovintiv to Neutral, Lowers Price Target to $53 By Benzinga Newsdesk Today, 4:40 AM JP Morgan analyst Arun Jayaram downgrades Ovintiv (NYSE:OVV) from Overweight to Neutral and lowers the price target from $59 to $53. OVV